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A B S T R A C T
Placebo is the use of the substance or procedure without specific activity for the condition that is trying to be healed. In
medicine, benefits of placebo effect are used since 1985 and 1978 placebo effect was first scientifically confirmed. It was
found that placebo induced analgesia depends on the release of endogenous opiates in the brain and that the placebo ef-
fect can be undone using the opiates antagonist naloxone. Functional magnetic resonance imaging of the brain showed
that placebo analgesia was obtained regarding the activation and increased functional relationship between ant. cingu-
late, prefrontal, orbitofrontal, and insular cortex, nucleus accumlens, amygdala, periaqueduktalne gray matter and spi-
nal cord. Placebo also facilitates descending inhibition of nociceptive reflexes through periacvaeductal gray substance.
Placebo effect can be achieved in several ways: by using pharmacological preparations or simulation of operating or
other procedures. This phenomenon is associated with perception and expectation of the patient. To achieve the effect of
placebo it is essential degree of the suggestions of the person who prescribe a placebo, and the degree of belief of the person
receiving the placebo. Expected effect of placebo is to achieve the same effect as the right remedy. Achieved placebo effect
depends on the way of presentation. If a substance is presented as harmful, it may cause harmful effects, called »nocebo«
effect. Placebo effect is not equal in all patients, same as the real effect of the drug is not always equal in all patients. Ap-
plication of placebo in terms of analgesia will cause a positive response in 35% of patients. Almost the same percentage
(36%) of patients will respond to treatment with morphine in medium doses (6–8 mg). Therefore, one should remember
that response to placebo does not mean that a person simulates the pain and then it is unethical to withhold the correct
treatment especially in light of findings that the prefrontal cortex is activated expecting liberation of pain and how this
action reduce activities in brain regions responsible for sensation of pain (thalamus, somatosensory cortex and other
parts of the cortex). However, the use of placebos is ethically, legally and morally very dubious. The basis for the placebo
effect is deception. It undermines honest relationship and trust between doctor and patient which is extremely important
for successful treatment. Consciously giving placebos to patients for a condition that can be adequately treated, with prej-
udice the right of patients to the best care possible, opens up many bioethical issues. Despite all the current knowledge
level, placebo effect remains still a scientific mystery.
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Introduction and Historical Aspects
Placebo is a drug or treatment which produces no spe-
cific biologic effects on the medical condition or symptom
which ought to be cured1. Placebo effect is also universal
phenomenon which is present in practice of medicine
from its very beginnings1,2. The word placebo is the ini-
tial world of psalm 116:6 »placebo Domino in regione
vivorum« (I will please the Lord in the land of living be-
ings). This psalm was spoken by paid people above the
graves of wealthy individuals2. During centuries there
was no many knowledge about real mechanism for treat-
ment of diseases. We have to assume that many of treat-
ments used in pre-scientific era were based on placebo
effect.
In 1811 Robert Hooper in »Quincy’ s Lexicon-Medi-
cum« described placebo as »an epithet given to any medi-
cine adapted more to please than benefit to the patient«.
Although Richard Cabot in 1903 says that »I have not yet
found any case in which a lie does not do more harm than
good«, in 1955 surgeon Henry Beecher discover that pa-
tients treated by enthusiastic surgeons have better out-
come than those one treated by skeptic surgeons3,4. He
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published in JAMA paper named »The powerful placebo«
and opened new era on placebo use. Austin Bradford Hill
designed the first randomized trial and use of placebo
started in clinical trials under the assumption that place-
bos has no efficacy in specific treatment effect. After
many double-blind control randomized clinical trials were
conducted over the world, investigators noticed that pla-
cebo sometimes has unexpected outcomes almost equally
powerful as active substance with which placebo was
compared. Although this observation was not confirmed
by evaluation of 130 controlled trials and 52 randomized
controlled trials, some investigators start to analyze pla-
cebo effect in healthy and sick people. These analytical
results are substantial data about placebo effect; espe-
cially in the field of pain5.
In modern medicine, placebo effect is defined »as the
part of the therapeutic response that is not attributable
to the properties of active ingredients«6,7. Placebo treat-
ment refers to an inert agent or treatment and placebo
effect refer to an outcome. While placebo is conducted to
desirable consequences in the patients, nocebo (»I will
harm«) is the phenomenon that is opposite to placebo6,7.
Nocebo effect is present if negative effect occurs in expec-
tations of negative occurrence. Both, placebo and nocebo
effects are complex mechanisms and placebo effect was
specially investigated in pain analgesia studies7,8.
As we know, the pain is the oldest phenomenon for
human life, an unpleasant emotional experience, multi-
dimensional and fully personal experience that’s under
the influence of many cultural, ethnic and linguistic dif-
ferences. Today we know very much about pathogenesis
of pain and we have many analgesic drugs and therapeu-
tic procedures for relieving a pain7,8. Placebo analgesia is
the most investigated models of placebo response. But,
still we can hear from medical stuff that »patient is exag-
gerate with his pain«, because placebo injection of glu-
cose gave him pain relief and that kind of solving pa-
tients pain is used by significant number of clinical and
generally practice doctors.
Aim of this article is to present the most recent find-
ings in field of placebo induced analgesia and to devote
attention of medical stuff on fact that pain relief after
use of placebo doesn’t mean that patient wasn’t suffered
from pain.
General Data about Placebo
The various forms of placebo effects were investi-
gated. Despite the one or other situation, most of popula-
tion can be placebo sensitive with different consistency of
the placebo response6,7. Contextual factors (conditioning,
expectancy and drug related instructions) predict pla-
cebo response. It seems that use of multiple pills, more
colorful, bigger and more expensive drugs produce higher
magnitude of placebo response. Also, intravenous injec-
tions are more powerful than intramuscular, and placebo
analgesia can show somatotropic distribution8,9.
Placebo effect is not the same in all patients, which is
not surprising because even the effect of a real cure is not
always the same for all patients. In contrast to these pa-
tients in whom we achieved a response after administra-
tion of placebo, in patients with Alzheimer disease we
will not get a response to placebo due to nonfunctional
prefrontal cortex which is responsible for realizing a
sense of expectation1,6,10,11.
The length of a placebo effect is different. For panic
disorder placebo can be an effective over 8 weeks, 6
months for angina pectoris and even two and a half years
in rheumatoid arthritis. In mild pain, after verbal sug-
gestion, placebo effect may be much stronger and persist
even after the tenth application3,7,10–12.
Placebo and Analgesia
In terms of analgesia, placebo will cause a positive re-
sponse in 39% of patients. Almost the same percentage
(36%) of patients will respond to treatment with mor-
phine. Placebo analgesia can be quick and powerful; if
subject believe that its receiving potent pain killer, by for
example intravenous injection, the pain intensity can
drop out for 2–5 points (out of 10) on visual analogue
scale (VAS). Measuring by efficacy index (pain decrease
with placebo/pain decrease with morphine) is 0,56 which
means that placebo is effective 56% as a standard dose of
morphine!10,11,13.
The use of placebo in the treatment of pain has shown
that the result is better if the pain is more intensive. Pla-
cebo also extend the period through which the patient
can tolerate the pain6,7,13.
Benedetti was comparing benefit in patients with
postoperative pain due to the »open« and »hidden« ad-
ministration of analgesics. It proved advantage of the
»open« treatment administration14. Also, the placebo ef-
fect occurs only if the patient knows that he received it
because action is based on the fact that the brain, expect-
ing relief from pain, start to produce endogenous opiates.
Except this path, placebo analgesia also includes opiate
downward path for the pain control which inhibits pain
by processing it the spinal cord and thus reduces the re-
sponse to pain in the brain14–16.
Common Principles of the Placebo Effect
Hróbjartsson and Peter Gotzsche examined the na-
ture of the placebo effect. The research was published in
2001 and 2004 when they published a follow-up study.
They concluded that in the group that received placebo
there was no statistically significant improvement com-
pared with group which did not receive therapy17,18. Also,
there was no significant placebo effect in studies that
measured objective outcomes (such as blood pressure).
Placebo effect can only be proven in studies where the
outcome (success or failure of therapy) was reported by
the patient. Finally, considering that in clinical studies,
patients do not know which treatment they receive, the
authors concluded that testing of the placebo effect do
not have great significance in clinical studies17–19.
R. Dobrila-Dintinjana and A. Na~inovi}-Duleti}: Placebo in the Treatment of Pain, Coll. Antropol. 35 (2011) Suppl. 2: 319–323
320
At 2010 Goffaux et al modeled the placebo effect9. As
we mentioned above, in induction phase therapeutic
message and method of administration have a great im-
pact on placebo effect. Reassuring message has been
shown to provide quick pain relief while message with
uncertainty can induce hyperalgesia-nocebo effect. Pa-
tients convinced that they’ll have better follow up and es-
timation of side effects has better placebo effect. If pla-
cebo is congruent with individual’s beliefs and values,
effect will be higher7,9.
In next phase, psychological mechanisms (which in-
clude past experiences of patient) are activating neuro-
chemical and neurophysiological mechanisms. Those are
responsible for the emergence of placebo effect9,16,19.
Imaging Approach to Placebo
For decades the main problem in pain analgesia was
to notice and quantify the pain. The problem is bigger be-
cause there are not existing objective biological markers
for pain. Many scales and questionnaires are developed
to facilitate the pain measurement9,20.
Today, several new imaging modalities are enhancing
the pain research: Single Photon Emission Computed
Tomography (SPECT), functional magnetic resonance
imaging (fMRI) and positron emission tomography (PET).
Those imaging modalities are opening objective approach
for the pain and pain relief researches21.
In 2002 Petrovic et al confirmed the increased activity
in anterior cingulated cortex (by functional magnetic res-
onance imaging of brain) during placebo and opioid in-
duced analgesia22. Anterior cingulated activity is also ac-
companied with activity in periaqueductal gray matter-
-mesencephalic region. When radioactive m-opiate recep-
tor traces were used, investigators found that opiate se-
cretion increase significantly in the limbic circuit during
expectations of pain relief22–24. Activation of endogenous
opiate system does not fully explaining placebo analgesia
due to fact that non steroidal anti-inflammatory drugs and
others are mediated by other unknown mechanisms24–26.
For placebo analgesia, together with opiate system is
involved dopaminergic »reward system«; subjects in whom
the activation of this system is stronger are better pla-
cebo responders. Placebo effect is increasing the activity
of dopaminergic cells in the nucleus accumbens27. There-
fore, nocebo effect can be tied to a deactivation of dopa-
minergic and opiate system; or nocebo suggestion is pro-
ducing anxiety which activates the cholecystokinin (po-
tent opiate antagonist) related pro-nociceptive system and
also descending hypothalamus-pituitary gland axis15,27,28.
Foundations of Placebo Effect
Psychophysiological mediators are conditioning, cog-
nition, motivation and emotions; endorphins, dopamine
and others neuromodulators and neurotransmiters are
also involved6,29. Conditioning and expectations of relief
can be connected to nocebo effect.
There are many examples how placebo works due to
conditioning theory; theory based on Pavlovian stimulus
substitution concept30,31. If placebo is described as mus-
cle relaxant it will cause such relaxation, and if it is de-
scribed as opposite, it will produce muscle tension. On
the other side, patients which are frequently taking the
same shape, color, taste and size of pill for some condition
(headache, heart pain) if after several associations pla-
cebo is given to them for same condition, they will ob-
serve pain relief30–32.
On those observations Goldstein (1962) developed
expectance theory for placebo response which is con-
nected to patient expectation33. Patient perception and
expectations are enhanced trough patient-doctors rela-
tionship (placebo response was increased from 44% to
62% with doctors encouraging), differences in size (large
pills better than smaller) and color of placebo pills (hot
colored pills are working as stimulants pills and cold col-
ored pills as depressants)33–35. But same supstance causes
both the stimulation and depression, depending on the
description that was used for supstance (conditioning!).
Thus, conditioning and expectation are interwoven toge-
ther with other factors (motivation, emotions, subjective
experience, quality of life, ect); and some still unknown
in enabling placebo effect33–35. If doctor who prescribe
placebo medication/intervention has optimistic, warm
and confidently approach to patient placebo showed hi-
gher magnitude of response6,9,35,36.
Motivation (a patients desire for relief) can explain a
large part of placebo effect, but motivation failed to pro-
duce placebo response in various kind of pain (for exam-
ple burning pain)37. Although stress is increasing level of
pain and distress, in some point can also produce stress-
-induced analgesia. So anxiety can produce stress-in-
duced analgesia, but also can (through motivation and
expectancy) produce higher level of placebo response. It is
not clear whether anxiety is cause or consequence of pla-
cebo36,37. In studies of placebo analgesia, only subjective de-
crease of anxiety was predictor of placebo response6,9,37.
Placebo analgesia can be viewed also as »meaning re-
sponse«. Moerman define the physiological and psycho-
logical effects of meaning in the treatment of disease;
when placebo is used the response is connected to inert
treatment or drug38. Various factors can influent the
»meaning of treatment«, especially doctors-patients rela-
tionship. Among other facts, this is why placebo has
better outcome in open protocols versus blind randomi-
zed clinical trials38,39. Conditioning, expectance and mea-
ning response are not part of patients emotions while re-
ceiving drug in blind randomized clinical trial; placebo
response will be better if patient is encouraged by her/his
doctor6,9,12,39.
When we are discussing placebo analgesia we must
not forget fact that culture is playing specific role in per-
ceiving and interpreting pain; the description of pain
vary among cultural different countries. When placebo
analgesia response is studying, biopsychosocial model
must be taken into consideration. It can be a point for
understanding placebo on the different corners of view:
R. Dobrila-Dintinjana and A. Na~inovi}-Duleti}: Placebo in the Treatment of Pain, Coll. Antropol. 35 (2011) Suppl. 2: 319–323
321
brain imaging, cognitive and emotional behavior toge-
ther with interactions between different cultures40.
Imaging studies provide us new data of how brain ac-
tivity was related to cognitive inputs (expectations of
pain relief). Some imaging studies confirmed that data
from neuropharmacologic studies about influence of cog-
nitive input on modulating physical and emotional states
through endogenous opiate system40,41. This studies also
showed how brain is able to use cognitive issues for acti-
vation of some functional areas41,42.
Since last decade placebo was described in behavioral
terms. Placebo response increase the chance of organism
to respond positively for any external intervention and it
is now clear that placebo must be the part of »embedded«
endogenous physiological responses which are signifi-
cant for self-preservation6.
Placebo effect depends on genetic variation too. These
findings are still in their early stages and more re-
searches are necessary. So far, it was discovered that pa-
tients with social behavior disorders inherited variant of
the gene for tryptophan-hydroxylase-2, which is associ-
ated with reduced activity in nucleus amigdala and cau-
ses greater sensitivity to placebo43.
Placebo is under influence of many intrinsic and ex-
trinsic factors, it is mediated by psychological and physi-
ological mechanisms and its involving endogenous opiate
system.
Clinical Practice and Ethical Consideration
Using placebos deeply affects the relationship be-
tween patient and doctor. If the patient discovers that
placebo has been prescribed instead of the drug it can sig-
nificantly impair their interoperability.
But in every day clinical practice sometimes we are
forced to deal with decision of using placebo and many of
clinicians use it. However, regardless of the seriousness
of the situation that could happen, survey conducted in
Denmark showed that 48% of family physicians, in cer-
tain situations will recourse to the use of placebos. Most
often this is used when prescribing antibiotics, even
though we know that this is a viral infection or when pre-
scribing vitamin when patient complains of fatigue44.
In United Kingdom law prohibits the use of placebo,
but despite of that 24% of clinicians use it and another
18% of them use it depending on circumstances45.
Therefore is not surprisingly that American Pain So-
ciety at 2005 published a paper on the use of placebo in
clinical research and patient care. Their conclusions
were that »the deceptive use of placebo and the misinter-
pretation of the placebo response to discredit the pa-
tients pan report is unethical and has to be forbidden«
and that »when using placebos, doctors have an ethical
obligation to ensure that placebos are not used to decep-
tion, punishment or under-treatment of patient with
pain«45.
Three years later, in USA a recent survey of 679 phy-
sicians, found that about half of them prescribed placebo
treatments on a regular basis! Most (62%) said that such
a practice is ethical; mostly of them are internists and
rheumatologists46. They think that patients will benefit
from positive expectations, not because the doctors think
that treatment will have a physiological effect on the pa-
tient condition. They are using saline injections, sugar
pills, but also over-the-counter analgesics (41%), vita-
mins (38%), antibiotics (13%) and sedatives (13%) as pla-
cebos. They describe to their patients that prescribed
medicine is uncommon for their health condition, but
might be beneficial46. Colleagues working in hospitals
less frequently use placebo than general practice doc-
tors45,46.
Conclusion
In conclusion we can say that base of placebo is decep-
tion. It spoils honest relationship and trust between doc-
tor and patient which is an extremely important link in
the treatment. Administering a placebo instead of drug is
unethical, and contrary to the Hippocratic Oath that all
doctors swear47.
Consciously providing placebos to patients for a con-
dition that can be properly treated, raises the question
about patient right on the best possible care, and open
many bioethical issues. We must ask ourselves whether
encouraging the patient, providing support and warm
words in combination with placebo would be sufficient to
administer the right medications at lower doses, and
again on the other hand, if the same would be ethically
correct, and how to deal with those who do not believe?
What to do with patients who have objective obstacles
(e.g. use of morphine for respiratory insufficiency in pa-
tient with burns) appropriate treatment cannot be pro-
vided – whether it’s justified to administer a placebo?
The concept of placebo and its effectiveness is cer-
tainly one of the most widely used concepts in medicine
and time will surely provide answer for at least some of
these questions. Until then we should act according to
our conscience and ethical principles.
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PLACEBO U LIJE^ENJU BOLI
S A @ E T A K
Placebo je upotreba tvari ili primjena postupka bez specifi~ne aktivnosti za stanje koje se poku{ava lije~iti. U~inak
placeba u medicini je bio znanstveno dokazan 1978. g. Prona|eno je da analgezija uzrokovana placebom ovisi o otpu{ta-
nju endogenih opijata u mozgu i da se placebo u~inak mo`e poni{titi upotrebom naloksona (antagonist opijata). Funk-
cionalna magnetska rezonanca mozga pokazala je da se placebo analgezija odr`ava poradi aktivacije i poja~anog me|u-
sobnog funkcioniranja izme|u odre|enih dijelova mozga (anterior cingulata, prefrontalni, orbitofrontalni i insularni
korteks, nucleus accumlens, amygdala, periaqueduktalna siva masa i le|na mo`dina. Placebo tako|er olak{ava descen-
dentnu inhibiciju nociceptivnih refleksa kroz periaquaeduktalnu sivu supstancu. Placebo u~inak se mo`e dobiti na vi{e
na~ina: upotrebom farmakolo{kih preparata ili simulacijom odre|enih postupaka. Taj fenomen je povezan s percep-
cijom i is~ekivanjem pacijenta. Va`an je i stupanj sugestije osobe koja propisuje placebo kao i stupanj vjerovanja osobe
koja prima placebo. O~ekivani u~inak placeba je dosti}i u~inak pravog lijeka. Placebo u~inak ovisi o na~inu prezentacije.
Ako se tvar prezentira kao {tetna, ona mo`e prouzro~iti {tetne u~inke, tzv. »nocebo« u~inak. Placebo u~inak nije isti u
svih pacijenata,ba{ kao {to ni u~inak pravih lijekova nije isti u svih pacijenata. Aplikacija placeba u analgetske svrhe
daje pozitivan u~inak u oko 35% pacijenata. Gotovo isti postotak (36%) pacijenata }e odgovoriti na dozu morfija od 6–8
mg. Stoga, treba zapamtiti da odgovor na placebo ne zna~i da osoba simulira bol i neeti~no je ne primijeniti pravi lijek
posebice u svjetlu saznanja da se prefrontalni korteks aktivira u is~ekivanju oslobo|enja od boli. Ta aktivacija smanjuje
aktivnost u regijama mozga odgovornima za osje}aj boli (talamus, somatosenzorni dio korteksa). Ipak, upotreba pla-
ceba je eti~no, zakonski i moralno vrlo dubiozna. Osnova placeba je obmana. Ona potkopava po{teni odnos i povjerenje
izme|u doktora i pacijenta koji je izuzetno va`an za uspje{no lije~enje. Svjesna primjena placeba u pacijenata ~ije stanje
se mo`e adekvatno lije~iti s oduzimanjem prava pacijenta na najbolje mogu}e lije~enje otvara mnoga bioeti~ka pitanja. S
znanstvene strane, bez obzira na sada{nji nivo znanja, placebo i njegovi u~inci ostaju znanstvena misterija.
